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Date Table of Contents  Introduction The objective of this research is to elucidate the relationship between the action of the transcription factor, Stat5a, and the regulation of programmed cell death in the mammary gland in order to establish the role of Stat5a in the development of breast cancer. This will be achieved through the development of a unique mouse model of breast cancer and the molecular analysis of the signaling pathways critical for the activation of this factor. This mouse model will permit evaluation of specific molecules involved in the Stat5a signaling pathway as modulators of involution and tumorigenesis.
Body
This research project began with interbreeding of the WAP-TGFcx transgenic and Stat5a knockout mouse lines and to provide a detailed study of the effects of Stat5a deletion on WAP TGFcc-induced tumor progression. This combination transgenic/knockout mouse line (TGFcx/Stat5aKO) was established and was expanded through standard breeding protocols to generate sufficient experimental and control mice for the tumorigenesis studies. After 8 months of breeding and data collection it was evident that the absence of Stat5a did have an effect on the development of tumors in the WAP-TGFcc transgenic tumor model. In the presence of TGFa overexpression, complete genetic deletion of Stat5a delayed initial mammary tumor development by 6 weeks. This preliminary data was presented in a poster format to the Breast Cancer Think Tank at Chantilly, Virginia. The alteration in the progression of involution was confirmed by histological analysis. WAP-TGFac transgenic mice have a significant delay in the onset of involution at the end of lactation. This delay is suggested to be one of the mechanisms for mammary tumor formation in this mouse model. It was observed that TGFca/Stat5aKO mammary glands underwent a significant reorganization and deletion of cell structure during involution. These changes replicated those observed during involution of a normal mammary gland. This observation suggested that the absence of Stat5a in the TGFc/Stat5aKO mice was allowing involution to occur and possibly reducing the tumorigenic capacity of the epithelium. Stat5a requires phosphorylation in order to be activated and is normally rapidly dephosphorylated at the beginning of involution(within 12 hours). Phosphorylation analyses of the tissues from WAP-TGFc transgenic mice revealed that Stat5a was inappropriately phosphorylated during involution. This provided evidence that the EGF signaling pathway was activating Stat5a during involution and preventing the regression of the epithelium. The EGF pathway was simultaneously activated implicating the EGF-dependent signaling kinase, MAPK, as the molecule initiating this phosphorylation event. This confirmed our earlier suspicions about the potential action of TGFQx on Stat5a signaling in the mammary gland. Detailed molecular analysis of proliferation and programmed cell death levels revealed that there was an increase in apoptosis in the TGFcc/Stat5aKO mouse when compared to the WAP-TGFct transgenic control gland. Suprisingly, apoptosis was increased during late pregnancy in the TGFa/Stat5aKO glands when normally cell death is low or absent in the wildtype gland. This was the first evidence that Stat5a can act as a survival factor for mammary epithelium. These experiments demonstrated that the absence of Stat5a affected the initiation of involution and the levels of apoptosis in the WAP-TGFcX mammary gland. This data lead us to conclude that Stat5a can mediate signaling from the EGF receptor and can influence the progression of EGF-initiated breast cancer.
6
The absence of Stat5a delayed the initial appearance of tumor formation by 6-8 weeks. It did not completely abrogate the appearance of tumors and the rate of tumor formation was the same as the control group. This suggested that the process of involution can remove significant numbers of cells that could potentially contribute to the development of tumors. But it also suggested that there remained sufficient cells after the process of involution, that could respond to EGF-activated signaling, to initiate transformation of the epithelium. The data generated was sufficient to write and submit a manuscript Vol. 10, 685-694, October 1999 is unknown. The prolactin-activated transcription factor has a crucial role in the regulation of cell death during Stat5a 3 is essential for the development and differentiation of mammary gland involution. In a transforming growth the mammary gland (4). Stat5a phosphorylation sharply defactor-a transgenic mouse model that exhibited clines within 12 h after weaning, suggesting a role in the delayed mammary gland involution, the absence of onset of involution. In fact, Stat5a has been implicated in the
Stat5a facilitated involution -associated changes in
regulation of apoptotic processes in other tissues (5, 6) . morphology of the gland and the extent and timing of Mammary gland involution can be separated into two moprogrammed cell death. These Stat5a-dependent lecularly and morphologically distinct phases. The first phase changes also affected epidermal growth factor is defined by changes in the expression patterns of genes receptor-initiated mammary gland tumorigenesis.
involved in milk synthesis (WAP and ornithine decarbox-Overexpression of the transforming growth factor a ylase), cell survival and death (Bax, Bcl-2, Bcl-xs, SGP-2, transgene in the mammary epithelium reproducibly interleukin-converting enzyme 1, and p5 3 ), and proteins that generated mammary hyperplasia and tumors. In the act to regulate potential survival factors (insulin-like growth presence of the activated epidermal growth factor factor-I, insulin-like growth factor-binding protein 5, and receptor, deletion of Stat5a delayed initial hyperplasia TGF-)3) and modulate interactions with the extracellular maand mammary tumor development by 6 weeks. These trix (tissue inhibitor of metalloproteinase 1; Refs. 3 and 7-11). observations demonstrate that Stat5a is a survival Importantly, dephosphorylation of the prolactin-dependent factor, and its presence is required for the epithelium transcription factors Stat5a and Stat5b can be detected of the mammary gland to resist regression and within 12 h of the initiation of involution (12). Despite the high involution-mediated apoptosis. We also suggest that levels of apoptosis early in involution, the integrity of the Stat5a is one of the antecedent, locally acting alveolar basement membrane is not disrupted. The second molecules that initiate the process of epithelial phase of involution is characterized by increases in the exregression and reorganization during involution.
pression of proteins and genes involved in reorganizing the extracellular matrix (gelatinase 1, stromelysin 1, and uroki-Introduction nase plasminogen activator) and abrogation of milk gene Involution is the phase of mammary gland development that expression. These molecular changes precede the dramatic remodels the molecular and morphological characteristics of degradation of the lobuloalveolar acini and the absorption of the gland after lactation. The systemic levels of prolactin, one apoptotic cells. It is presumed that changes in the concenof the dominant hormones in the stimulation and mainte-trations of the systemic hormones prolactin, oxytocin, and nance of lactational competence of the gland, decreases at progesterone, in concert with changes in the activity of lothe onset of involution (1). The characteristics of the biolog-cally acting factors, initiate and stimulate the process of involution.
The importance of the Stat proteins in the growth and transgene (Stat5aKOTGFa mice). H&E-stained mammary differentiation of many cell types is exemplified by their ubiq-glands from TGFaTG, Stat5aKO, Stat5aKOTGFa, and WT uitous expression and widespread utilization in the signal nontransgenic control mice at day 18 of pregnancy and days transduction pathways of multiple cytokines (13). Stats are 1, 3, and 7 of involution were examined by light microscopy capable of transmitting both differentiative and proliferative ( Fig. 1) . Morphological differences were observed between signals, depending on the cellular and receptor context (14, the TGFaTG and Stat5aKOTGFa mammary glands within the 15). In the mammary gland, Stat5a activation by prolactin is first pregnancy and involution. TGFaTG mammary glands required for functional differentiation of the epithelium during contained hyperproliferative alveoli and ducts. Alveolar lupregnancy and lactation (4, 16) . Singular tyrosine phosphomina contained heterogenous eosin-positive staining materylation by the prolactin receptor-associated intracellular ki-rial. A significant increase in the number of stromal cells was nase Jak-2 is obligatory to maintain Stat5a transcriptional evident, in addition to increased deposition of stromal collaactivity (17). However, novel alternative mechanisms of reg-gen ( Fig. 1 /. Involution was delayed in the TGFaTG mice, as ulating Stat5a activity have been identified. . Some cell loss and condensation of vated signal transduction can tyrosine-and serine-phospho-lobuloalveolar structures was observed during involution, but rylate multiple isoforms of the Stat5a molecules (18).
the gland lacked the dramatic epithelial regression of the WT Furthermore, truncated forms of Stat5a have transcriptional gland ( Fig. 1 , n versus p). Mammary tissue from pregnant dominant negative activity (19, 20) and have been linked to Stat5aKOTGFa mice was histologically similar to pregnant the regulation of apoptosis (5). In the liver, EGF can stimulate tissue from TGFaTG mice but contained more epithelium phosphorylation and nuclear translocation of the Stat5a isothan observed in the glands of Stat5aKO mice ( Fig. 1, a-d ). form, Stat5b (21). Importantly, serine phosphorylation of Secretory structures appeared to be more uniform and Stat5a by the prolactin-independent, MAPK pathway has lacked the observed heterogeneous precipitations in the albeen identified, (22) including a direct association between veolar lumens. During involution, the Stat5aKOTGFa gland Stat5a and the serine kinase ERK-1/2(MAPK) (23). Serine remodeled more rapidly and extensively than the TGFaTG phosphorylation by the MAPK pathway is required for tran-gland ( Fig. 1 , o versus p). This effect was enhanced after scriptional activity of Statl and Stat3, but serine phospho-subsequent rounds of pregnancy and involution (data rylation is not obligatory for prolactin-dependent transcrip-not shown). The primary and secondary ducts of the tional activity of Stat5 proteins (24). Taken together, these Stat5aKOTGFa mice lacked concentrations of hyperplastic data imply that Stat5a activity can be regulated by the pro-cells like those found in the TGFaTG mice. On rare occalactin and EGF signaling pathways and possesses diverse sions, hyperplastic regions were evident after three or more functional roles within a single cell that are dependent on its rounds of pregnancy in Stat5aKOTGFa mice (data not phosphorylation state and expressed isoforms.
shown). Initiation and progression of breast cancer rely on the Apoptosis and Proliferation Levels Are Altered in the inappropriate temporal and qualitative activity of normal cel-Stat5aKOTGFa and TGFaTG Mice. High levels of apoptolular signaling pathways (25). These alterations in signaling sis, decreased proliferation, and the collapse of lobuloalveoactivity often disrupt the normal mechanisms of mammary lar structures in the mammary epithelium are hallmarks of gland development. In one mouse model (WAP-TGF-a), involution in the mammary gland (7). To establish and deoverexpression of TGF-a, which binds to and activates the fine the characteristics of mammary involution in the EGFR, delays mammary involution and transforms the mam-Stat5aKOTGFa and TGFaTG mice, the levels of apoptosis mary epithelium (26). The prolactin signaling pathway has and proliferation were analyzed by TUNEL and BrdUrd imbeen implicated in loss of normal epithelial differentiation (4, munohistochemistry, respectively (Tables 1 and 2). WT 16) and transformation (27, 28) . The role of Stat5a in tumorglands exhibited increased levels of apoptosis within 1 day of igenesis is implicated by the appearance of Stat5a overex-the initiation of weaning and exhibited maximal levels at day pression in leukemic (29, 30) and oncogenic (31) transformed 3, as expected (9, 35) . Consistent with an inhibition or delay cells. Additionally, constitutive activation of the Jak/Stat in involution in the TGFaTG gland, the number of apoptotic pathway occurs in multiple leukemia-, v-abl-, and human cells was slightly reduced at day 1 of involution compared T-cell lymphotrophic virus-transformed T cells (32, 33), and with WT and Stat5aKOTGFa glands ( Fig. 2A ). Apoptosis was specific inhibition of constitutive Jak-2 activity in acute lym-reduced in the TGFaTG gland at day 7 when compared with phoblastic leukemia can block cell growth and induce cell WT gland at day 7. Whereas Stat5aKOTGFa mammary death (34). We used the WAP-TGF-a transgenic and Stat5a-glands at day 18 of pregnancy (P = 0.02) and at day 1 of null mouse models to explore the in vivo role of Stat5a in involution (P = 0.015) had significantly higher levels of apomammary gland involution and tumorigenesis. ptosis than TGFaTG and WT mammary glands over the same time period, the levels were similar at days 3 and 7. Inter-Results estingly, Stat5aKO mammary glands also displayed signifi-Delayed Mammary Involution in the TGFaTG Mice Is Cur-cantly high levels of apoptosis at day 18 of pregnancy and tailed in the Absence of Stat5a. The contribution of Stat5a day 1 of involution (P = 0.03). in regulating involution and the establishment of mammary Levels of proliferation, as measured by BrdUrd incorporatumors was investigated in mice that carried the TGF-ax tion, were equivalent in mammary tissue of pregnant transgene (TGFaTG mice) or were null for the Stat5a gene Stat5aKOTGFa, TGFaTG, Stat5aKO, and W-T mice ( Fig. 2B ). (Stat5aKO mice) and in Stat5a-null mice that expressed the Generally, 6-10% of the cells in the pregnant gland were Apoptotic cells were observed in Stat5aKOTGFa mammary TGFaTG Mice. The WAP gene promoter has been exploited glands at day 18 of pregnancy and day 1 of involution in to target high-level expression of transgenes, including animals labeled exclusively with BrdUrd ( Fig. 2C, arrows) . TGF-ca, to the mammary epithelium of pregnant mice (36-
The appearance of apoptotic, BrdUrd-labeled cells demon-40). To assure that the hormonal and morphological changes Tables 1 and 2 . B, proliferation is higher in TG and KOTG mammary glands through involution. Proliferation levels in Stat5a-null TGF-a transgenic (KOTG), TGF-a transgenic (TG), Stat5a-null nontransgenic (NTGKO), and WT mammary glands after analysis by BrdUrd labeling. Values represent the percentage of cells (means ± SE) displaying the label in a minimum population of 1000 cells. Analysis was performed on mice during or immediately after their first pregnancy. Serial sections of tissue from the same mouse were used for determination of proliferation and apoptosis. A minimum of three mice were analyzed from each genotype. Total number of cells counted, 6.5 x 105. a, b, c, and d significant differences between TG and KOTG samples when compared with WT at day 1, 3, and 7 of involution. C, proliferation analysis of mammary gland in Stat5a-null TGF-a transgenic mammary glands. This figure demonstrates the appearance of BrdUrd-labeled apoptotic cells in late pregnancy (p18) and days 1 and 7 of involution (il and i7). Mice were injected 2 h before sacrifice with 20 /g/g body weight BrdUrd, as described in "Materials and Methods." Gray arrows, BrdUrd-labeled apoptotic cells. Black arrowheads, intact BrdUrd-labeled nuclei. Bar in p18, 100 Am.
associated with involution and the absence of Stat5a did not The EGFR-activated Serine Threonine Kinase MAPK disrupt transgene expression, TGF-a expression was evalu-Remains Active throughout Involution. Binding of TGF-a ated in mammary tissue of pregnant and involuting TGFaTG, to the EGFR initiates receptor dimerization and inherent ki-WT, and Stat5aKOTGFa mice. Northern blot analysis of nase activation, which stimulates the Ras/Raf/Mek signaling TGF-a transgene expression in TGFaTG and Stat5aKOTGFa cascade. To establish that the EGFR-dependent pathway mice revealed expression of an appropriately sized transcript was being activated by the expression of the TGF-a transat day 18 of pregnancy. Transgene expression persisted gene, Western blot analysis was performed on protein exthrough days 1, 3, and 7 of involution in multiple animals (Fig. tracts from Stat5aKOTGFa, WT, Stat5aKO, and TGFaTG 3). This expression pattern deviates from the expression of animals with an antibody that only recognizes the active the endogenous WAP gene, which declines at the initiation of (phosphorylated) form of MAPK. Active MAPK was detected involution (41) . Endogenous TGF-a expression was only dein TGFQTG and Stat5aKOTGFa mammary glands at day 18 tected in an overloaded lane containing wildtype tissue at of pregnancy and days 1, 3, and 7 of involution ( Fig. 4 TGFot EtBr A Fig. 3 . TGF-a transgene expression persists through involution in KOTG and TG mammary glands. Northern analysis of TGF-a expression in TG, KOTG, and WVT mammary glands. Total RNA (20 tg) was separated and analyzed on a single Northern blot. Each lane represents RNA from a single animal. Samples were collected from mice during or immediately after their first pregnancy. The TGF-a blot was exposed for 4 h at -70°C. EtBr, ethidium bromide staining of RNA.
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active MAPK were detected in the nontransgenic StatSaKO gland ( Fig. 4C ). Levels were also very low in pregnant and involuting WT mammary glands ( Fig. 4D) . A significant level of MAPK is present in the lactating, WT mammary gland. Stat5a Proteins Are Phosphorylated during Involution in TGFaTG and Stat5aKOTGFa Mice. Stat5a is phosphorylated on tyrosine 694 by Jak-2, which is associated with the dimerized prolactin receptor (13). Stat5a must remain phos-C phorylated to maintain its transcriptional activity. One of the earliest molecular events after the onset of involution is the dephosphorylation of Stat5a and Stat5b (42) . Immunoprecipitation and Western blot analysis of protein extracts from TGFaTG mice detected high levels of tyrosine-phosphorylated Stat5a and Stat5b at days 1, 3, and 7 of involution ( Fig.  5 ). Conversely, the phosphorylation of Stat5a and Stat5b was decreased at day 1 and remained low to day 7 of D involution in WT controls, as reported previously and shown in Fig. 5B (42) . Additionally, tyrosine-phosphorylated Stat5a and Stat5b were also detected by immunoprecipitation and A w Western blot analysis in multiple individual TGFaTG tumors (data not shown). Stat5aKOTGFa mammary glands, lacking Stat5b phosphorylation was detected on days 1, 3, and 7 of (D) mammary glands. 4L, a control sample from a WT, 4 day lactating involution relative to WT controls. mammary gland. a, a sample from a KOTG mammary gland after three pregnancies. p, a TG mammary gland after three pregnancies. Each TGF-a-initiated Mammary Tumorigenesis Is Delayed in immunoblot was stripped and reblotted with an antibody to MAPK to Stat5aKOTGFa Mice. The rat TGF-a transgene under condetermine loading, and the result is shown directly under the phosphotrol of the WAP gene promoter induces mammary tumors in rylated MAPK immunoblot in each panel. Arrows in A indicate the two subunits of MAPK, ERK-1 (top) and ERK-2 (boftom). mice bred ad lib after three pregnancies (26). The contribution of Stat5a to the establishment of mammary hyperplasias and tumors was investigated in TGFaTG and Stat5aKOTGFa mice. Stat5aKOTGFa and TGFaTG mice were bred ad lib abnormal hyperproliferation of glandular structures with reland examined after each round of pregnancy for palpable atively little hyperplasia. The latency of mammary hyperplahyperplasias and tumors. All 48 TGFaTG mice contained sia and tumor appearance and the histology of the hyperpalpable hyperplasia in multiple glands by the third preg-plasias and tumors were consistent with the results nancy. TGFaTG mammary glands consistently displayed a described previously (26). Hyperplasia and hypertrophy apswollen appearance by the second pregnancy, emblematic peared less frequently in the Stat5aKOTGFa mammary of hypertrophic glands and hyperplasias (data not shown).
gland. There was a significant difference in the rate of initial Gross histological examination revealed the presence of hyperplasia and tumor formation between the TGFaTG and multiple hyperplastic alveolar nodules in multiple glands.
Stat5aKOTGFa mice, (P = 0.003; Fig. 6 ). The initial appear-TGFaTG glands also contained fluid-filled cysts and stromal ance in the Stat5aKOTGFa mice was delayed 1.5 months proliferation. Some removed tumors were characterized by compared with the TGFaTG mice. In Stat5aKOTGFa mice presence is mandatory to avoid the initiation of PCD in mamantibodies. Samples were collected from mice during or immediately after mary epithelial cells. their first pregnancy. Immunoblots probed initially with p-Tyr were Despite the lack of known genetic targets for Stat5a in the stripped and reblotted with anti-Stat5a antibodies in the TG samples (5a15b; 5a/5b) or anti-Stat5b antibodies in the KOTG samples (5a/5b; involuting gland, there is evidence to suggest that prolactin 5a/5b), respectively, to determine protein loading. il, i3, and i7, days 1, 3, and Stat5a can control cell survival. Activation of Stat5a has and 7 of involution, respectively. B, Stat5a and Stat5b are dephosphorylated during involution. Stat5a and Stat5b phosphorylation was examined been implicated in the inhibition of apoptosis in T cells in NTGKO and WT mice mammary glands. Protein extracts were immu-through interleukin 2 (6) and interleukin 9 (43) signaling. In noprecipitated with anti-Stat5a antibodies (Stat5a, 1:2 X 105) or anti-addition, selection of apoptosis-resistant immature T cells Stat5b antibodies (Stat5b, 1:1 x 105) overnight. Immunoprecipitates were separated by PAGE and immunoblotted with anti-phosphotyrosine (p-Tyr, leads to the activation of a dominant negative form of Stat5a 1:1 x 103) antibodies. Samples were collected from mice during or im-(5). Prolactin can also stimulate cell survival in mammary mediately after their first pregnancy. Immunoblots probed initially with epithelial cells in vitro (44) , and prolactin and growth horp-Tyr were stripped and reblotted with anti-Stat5a antibodies or anti-Stat5b antibodies to determine protein loading. p18, il, 03, and W7, day 18 mone can promote cell survival in the involuting rat mamof pregnancy and days 1, 3, and 7 of involution, respectively. mary gland (2, 3). The presence of apoptotic cells in the mammary tissue of pregnant mice that lack the Stat5a gene and express the TGF-a transgene suggests that cell dependthat did develop hyperplasias or tumors, usually only a single ence on the presence of phosphorylated Stat5a precedes gland was involved, as compared with multiple gland in-the actual systemic hormonal switch into involution. This volvement in the TGFYTG mice.
observation also implies that the Stat5a-dependent mechanism of apoptosis induction may be hormonally independent.
Discussion
We did not observe this apoptotic phenomena in the WT and Loss of Stat5a Activity Is an Early Event in Mouse Mam-TGF-a transgenic mice. This increased number of apoptotic mary Gland Involution. Dephosphorylation and hence incells during pregnancy was also detected in BrdUrd-labeled activation of the transcription factors Stat5a and Stat5b and Stat5aKOTGFa mice. Analysis of these glands revealed the de novo phosphorylation of Stat3 occur in the first phase presence of BrdUrd-labeled apoptotic cells at day 18 of within several hours of pup removal (42) , implicating the pregnancy and at days 1, 3, and 7 of involution. These cells Stats and prolactin as early regulatory molecules in the rereplicated their DNA and then proceeded directly into PCD.
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This association between the cell's ability to replicate its DNA phosphorylation of Stat5a and control apoptosis in the and the progression into the apoptotic program has been mouse mammary gland. reported previously (45) . Cells may be programmed to initiate Persistent Stat5a Activity Contributes to Mouse Mam-PCD before they enter the cell cycle; consequently, BrdUrd-mary Tumorigenesis, and Its Absence Acts to Delay Hylabeled cells undergoing apoptosis are detected. Interest-perplasitic Epithelial Formation. One of the dominant ingly, not all the cells in the Stat5aKOTGFcz pregnant gland pathways commonly altered in breast cancer is the EGF undergo PCD. This suggests that some cells have obviated signal transduction pathway (25, 54) . Gene deletion studies the requirement for Stat5a, possibly through an unknown in mice have demonstrated that the EGFR is not dispensable compensatory mechanism. Alternatively, these cells may for normal mammary development (55, 56) , and that aberrant have a unique differentiation state that precludes them from signaling through this receptor induces neoplastic growth entering the apoptotic pathway. and frank tumors (26, (57) (58) (59) . Using an EGF-dependent Despite persistent phosphorylation of Stat5a in involuting transgenic mouse model, we can now show that the persismammary tissue, TGFaTG mice did undergo involution-tent activation of Stat5a is linked to the transformation of the dependent epithelial reorganization and activation of PCD. mammary gland. We suggest that the transformation of the This morphological change was characterized by moderate mammary epithelium occurs at the expense of a loss of cell condensation of alveolar structures and loss of cells through survival regulation, which is contingent on the persistent the induction of PCD. We propose that the dephosphorylphosphorylation of Stat5a and permits the inappropriate suration of Stat5a is not the only guiding factor for apoptosis vival of epithelial cells. The appearance of tumors and hyprogression in the involuting mammary gland and that other perplasias in Stat5aKOTGFa mice suggests that the absence parallel signals may be required for the complete induction of of Stat5a will not completely block mammary epithelial transboth phases of involution (12).
formation, and that the TGF-c transgene can activate alter-Transgenic TGF-a Activates the EGFR and Ensures native (non-Stat5a) pathways to bypass PCD and involution Persistent Phosphorylation of Stat5a. TGF-a stimulates and support tumor formation. Such pathways may include the EGFR and activates MAPK through the Ras/Raf/Mek Stat5b, which, under specific circumstances, substitutes for signaling cascade. This is exemplified by the presence of the Stat5a (60). The involvement of a single gland in a majority of activated form of MAPK during involution in the TGFcuTG and the Stat5aKOTGFa tumors suggests that significant num-Stat5aKOTGFa mice. Persistent activation and phosphorylbers of potentially transformed cells are destroyed during ation of Stat5a in the TGFaTG mice could occur through involution. This loss of cells probably contributes to the obthree distinct mechanisms. The EGFR can directly phospho-served lower rate of tumor formation and the delay in initial rylate Statl and Stat3 in the absence of Jak activation (46- tumor appearance. In spite of single gland involvement, sur-48). Although direct phosphorylation of Stat5a by the EGFR vival of the Stat5aKOTGFa mice was no greater than that cannot be ruled out, it was not possible to coimmunopre-observed for the TGFuTG mice after initial tumor appearcipitate this receptor with anti-Stat5a antibodies in the ance. TGFuTG mammary gland (data not shown). Secondly, stim-Our findings that Stat5a is a survival factor and that its ulation of MAPK by EGF can lead to phosphorylation and absence reduces mammary tumorigenesis support findings nuclear translocation of the Stat5a isoform Stat5b in the liver from other settings. Prolactin and other type 1 cytokines do (21). Support for this mechanism comes from results de-possess mitogenic activity, implicating the associated Stat scribing that Stat5a and its shorter isoforms can be tyrosinemolecules with contributing to the mitogenesis of these orand serine-phosphorylated by prolactin (18), and Stat5a and gans (13). Constitutive Stat activity has been observed in Stat5b can be tyrosine-and serine-phosphorylated by pro-cells transformed by oncogenic viruses (32) and oncogenes lactin-independent, MAPK-dependent mechanisms (22, 49) . (61) and in leukemia cells (29). Moreover, constitutive acti-A direct interaction was recently demonstrated between vation of Jak expression can lead to transformation (27, 62). MAPK(ERK1/2) and Stat5a in growth hormone-dependent Stat5a Is a Survival Factor for the Mammary Epithesignaling (23). Growth hormone is known to influence mam-lium. The absence of Stat5a disrupts the prolactin-mediated mary gland involution, although this effect is not as dominant survival of the mammary epithelium. Whereas overexpresas that observed for prolactin (2). Thirdly, EGFR could acti-sion of TGF-c in the presence of an intact Stat5a results in vate Stat5a through Jak-2. The EGFR is known to use Jak-1 delayed involution, apoptosis and involution in the absence to activate Statl and Stat3 (14, 50) and can modulate Stat5 of Stat5a lead to elimination of the majority of the epithelium. expression in mammary epithelial cells (51) . Theoretically, the
The dephosphorylation or lack of de novo phosphorylation constitutively active EGFR in the TGFaTG and and inactivation of Stat5a that occur during involution in the Stat5aKOTGFa mice could stimulate Jak-2, although this WT gland are mimicked by the absence of Stat5a in the was not formally proven. Alternatively, EGFR could stimulate Stat5aKOTGFoa mice. Therefore, we propose that the presa secondary Jak, which inappropriately uses Stat5a as a ence of the activated form of this transcription factor prosubstrate that has been demonstrated in IFN--y signaling (52, longs cell survival, and its inactivation or deletion permits 53). Presumably, the stimulation of the EGFR kinase in the PCD to occur. These experiments demonstrate that Stat5a presence of the TGF-a transgene leads to phosphorylation can act as a survival factor for the epithelium of the mamand activation of a downstream kinase, possibly including a mary gland. In addition, they illustrate that the inhibition Jak, that maintains Stat5a in its phosphorylated state. We and/or disruption of the mechanisms that regulate this invosuggest that one or more of these mechanisms regulate the lution process are critical in mammary gland tumorigenesis.
The conclusions from this study lead us to hypothesize that overnight at 4°C with gentle rocking, and all incubations with antibodies the inhibition or disruption of Stat5a phosphorylation can and initial blocking were performed with 3% nonfat dried milk in 1 x TBST.
lead to protection from transformation in the mammary Detection was performed with the enhanced chemiluminescence kit according to manufacturer's protocol (Amersham) and exposed to Kodak gland. The application of Stat and/or Jak-specific tyrosine or (Rochester, NY) MR autoradiography film. Exposure times are between 1 s serine kinase inhibitors may be an approach to blunt the and 2 min. Immunoprecipitations with anti-Statha antibodies were carried development of mammary tumors originating from EGFR out as described previously (4). Stripping was performed by incubating deregulation, blots at 56°C in 6.25 mm Tris-HCI (pH 6.8), 2% SDS, and 1% I3-mercaptoethanol for 30 min. Blots were washed extensively in TBST and then blocked with 3% nonfat dried milk in TBST.
Materials and Methods
Northern Blot Analysis. Total RNA was isolated from fresh tissue by Materials. The TGF-o cDNA probe was a kind gift from Dr. David Lee homogenization in lysis buffer as described previously (63). RNA was (Lineberger Comprehensive Cancer Center, University of North Carolina, quantified by spectrophotometry and prepared for Northern blot analysis Chapel Hill, NC). The generation of the Statha antibodies has been de-by heating in loading buffer at 651C. Total RNA was separated by 1.5% scribed previously (63). Phosphorylated MAPK antibody was purchased agarose gel electrophoresis and transferred to Hybond N+ (Amersham) from Promega (Madison, WI). Anti-phosphotyrosine antibody was pur-nylon membrane by capillary transfer with 10 x SSC. After overnight chased from Upstate Biotechnology, Inc. (Lake Placid, NY). Goat antirab-transfer, the membrane was UV-irradiated and hybridized to each cDNA bit and rabbit antimouse secondary antibodies were purchased from probe in Quikhyb (Stratagene, La Jolla, CA). Hybridization for the TGF-o Transduction Laboratories (Lexington, KY).
cDNA probe was performed in Quikhyb (Stratagene) at 65°C for 16 h, Generation of TGFaTG and Stat5aKOTGFa Mice. WAP-TGFaTG followed by two washes in 1 X SSC and 0.5% SDS for 30 min, followed mice were a gift of Dr. Eric Sandgren (University of Wisconsin, Madison, by one wash in 0.1 X SSC and 0.5% SDS for 30 min at 56°C. Blots were WI Ref. 26). The generation of the Stat5a-null mice has been described hybridized for 16 h and then washed twice in 1 x SSC and 0.5% SDS for previously (4). TGFaTG mice were interbred with Statha-null mice 30 min, followed by one wash in 0.1 x SSC and 0.5% SDS for 30 min. (SvEvl29/C57B6) to generate F 1 founders that were hemizygous for cDNA and oligo probes were random-primed and Klenow-labeled with Stat5a deletion (StathaHT) and transgenic for TGF-a expression. Female [a-3 2 P]dCTP. After hybridization and washing, blots were exposed from Stat5aHTTGFa mice were bred with Stat5aHTTGFa males to generate 30 min to 24 h, as specifically described in the figure legends, to Kodak offspring that were transgenic for TGF-a and homozygous for deletion of MR autoradiography film at -70 0 C.
the Stat5a gene. These mice were backcrossed for five generations to BrdUrd and TUNEL Assays. Protocols for BrdUrd and TUNEL analgenerate a pure inbred Stat5aKOTGFa strain of mice. The same genera-ysis have been described elsewhere (64). Mice were injected 2 h before tion TGFaTG and control WT littermates was used for molecular analyses. sacrifice with 20 gg/g body weight BrdUrd labeling reagent, as described Confirmation of the presence of the TGF-o transgene was performed by by the manufacturer (Amersham). Each proliferation and apoptosis sam-PCR analysis with TGF-o forward primer 5'-TGTCAGGCTCTGGAGAA-pie counted represents a minimum of three random fields (at X200) and CAGC-3' and reverse primer 5'-CACAGCGAACACCCACGTACC-3'. a minimum of 1000 total cells/section for each mouse. A minimum of three Stat5a PCR was performed with two sets of primers to knockout (null) and mice per timepoint were collected and analyzed. The total number of cells WT alleles: (a) Stat5a forward (5'-CTGGATTGACGTTTCTTACCTG-3') and
counted for proliferation assay is 6.5 x 105. The total number of cells Stat5a reverse (5'-TGGAGTCAACTAGTCTGTCTCT-3') and (b) Neo for-counted for the apoptosis assay is 7.5 x 105. The number of mice ward (5'-AGAGGCTATTCGGCTATGACTG-3') and Neo reverse 5'-collected and the number of mice analyzed are listed by genotype and by TTCGTCCAGATCATCCTGATC-3'. PCR for all primers was performed timepoints (pregnancy day 18/involution day 1/involution day 3/involution with a denaturing step of 94 0 C for 3 min, followed by 30 cycles of 94'C for day 7) for apoptosis and proliferation, respectively: KOTG, 4/4/4/3 and 40 s, 56°C for 40 s, and 68'C for 40 s, followed by 10 min at 68°C. 4/3/3/3; TG, 3/5/3/5 and 3/3/3/5; WT, 3/4/5/3/ and 3/3/3/3; NTGKO, Genotype of the mice was confirmed after tissue collection by Northern 3/3/2/3 and 3/3/3/3. and Western blot analysis for TGF-o gene expression and absence of Hyperplasia and Tumor Analysis. Mice were palpated at the 18th Stat5a protein expression, respectively. All animals were housed and day of pregnancy for mammary hyperplasia, hypertrophy, and tumors. handled according to the approved protocol established by the Institu-Animals were scored for the presence of either hyperplasia or tumor at tional Animal Care and Use Committee and NIH guidelines, every pregnancy. Most animals were sacrificed at the third pregnancy by Mammary Gland Collection. Mammary glands were surgically re-anesthesia followed by cervical dislocation. In studies that required longmoved from anesthetized and cervically dislocated mice at day 18 of term breeding for tumor development, dams were rebred within 2 days pregnancy and days 1, 3, and 7 of involution. Day 1 of involution was after birth and removal of the pups. designated as 24 h after the morning that the pups were born. Pups were immediately removed from the dam after birth and fostered onto a WT Acknowledgments mother. The mammary lymph node was removed before homogenization of all glands. Tissues were prepared immediately for RNA and protein
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transgenic mice. Cancer Res., 55: 3915-3927, 1995. 158-165, 1997. 27. Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., 9. Lund, L. R., Romer, J., Thomasset, N., Solberg, H., Pyke, C., Bissell, Ross, T. S., Peeters, P., Van Rompaey, L., Van Etten, R. A., Ilaria, R., Jr., M. J., Dano, K., and Werb, Z. Two distinct phases of apoptosis in mam-Marynen, P., and Gilliland, D. G. Transformation of hematopoietic cell lines mary gland involution: proteinase-independent and -dependent path-to growth-factor independence and induction of a fatal myelo-and lymways. Development (Camb.), 122: 181-193, 1996. 15. Iwamoto, Y., Chin, Y. E., Peng, X., and Fu, X. Y. Identification of a 32. Migone, T. S., Lin, J. X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., membrane-associated inhibitor(s) of epidermal growth factor-induced sig-Franchini, G., and Leonard, W. J. Constitutively activated Jak-STAT pathnal transducer and activator of transcription activation. J. Biol. Chem., way in T cells transformed with HTLV-I. Science (Washington DC), 269: 273: 18198-18204, 1998. 79-81, 1995. 16. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, 33. Danial, N. N., Pernis, A., and Rothman, P. B. Jak-STAT signaling D., Wang, D., Brown, M., Bodner, S., Grosveld, G., and IhIe, J. The mammary gland undergoes extensive tissue remodeling and cell death at the end of lactation in a process known as involution. We present evidence that the prolactin-activated transcription factor, Stat5a has a crucial role in the regulation of cell death during mammary gland involution and can affect the progression of epidermal growth factor (EGF)-dependent mammary tumorigenesis. In a transforming growth factor-alpha (TGFC) transgenic mouse model, that exhibited delayed mammary gland involution, the absence of Stat5a facilitated involution-associated changes in morphology of the gland and the extent and timing of programmed cell death (PCD). These Stat5a-dependent changes also altered EGF receptor-initiated mammary gland tumorigenesis. Overexpression of the TGFcc transgene in the mammary epithelium reproducibly generated mammary hyperplasia and tumors. In the presence of TGFc overexpression, complete genetic deletion of Stat5a reduced the rate of tumor formation and delayed initial mammary tumor development by 6 weeks. These observations demonstrate that Stat5a is a survival factor and its presence is required for the epithelium of the mammary gland to resist regression and involution-mediated apoptosis. We suggest that Stat5a is one of the antecedent, locally-acting, molecules that initiate the process of epithelial regression and reorganization during involution. In addition, these studies suggest that disruption of the pathway which leads to Stat5a activation can affect the progression of tumorigenesis in the mammary gland. The in vivo relationship between the epidermal growth factor (EGF) and prolactin/Jak/Stat signaling pathways in mammary gland development and tumorigenesis was explored in transgenic mice which overexpress the TGF alpha gene (TGFuTG) in the mammary epithelium and lack the prolactin-activated transcription factor, Stat5a (Stat5aKO). We present evidence that Stat5a has a crucial role in the regulation of cell death during mammary gland involution and the development of EGF-dependent tumorigenesis. TGFaTG mice exhibit delayed mammary gland involution and the absence of Stat5a in the Stat5aKO/TGFctTG gland facilitated involution-associated changes in morphology and the extent and timing of programmed cell death in the mammary gland. Stat5a remained phosphorylated through involution in the TGFUTG mammary glands suggesting that Stat5a is constituitively phosphorylated and "activated" by the EGF signaling pathway. These results suggested that the TGFa epithelium is prevented from progressing into the normal pattern of involution and apoptosis by the "activated" form of Stat5a. Alternatively, the presence of activated Stat5a is required for the epithelium of the TGFaTG mammary gland to resist regression and involution-mediated apoptosis. These Stat5a-dependent changes also affected EGF-receptor initiated (EGFR) mammary gland tumorigenesis. Overexpression of the TGFu transgene in the mammary epithelium reproducibly generates mammary hyperplasia and tumors. In the presence of the activated EGFR, deletion of Stat5a delayed initial hyperplasia and mammary tumor development by 6 weeks. These observations demonstrate that Stat5a is a survival factor and its presence is required for the epithelium of the mammary gland to resist regression and involution-mediated apoptosis. This effect on involution can influence the development of mammary gland tumorigenesis. We are currently utilizing specific kinase inhibitors to block the phosphorylation of Stat5a by the EGFR signaling pathway in order to determine the mechanism of Stat5a activation. This work is supported by a grant from the DoD, USMIRMC to R.C.H. [DAMD17-99-1-9328] Oncogene (2000) Transforming growth factor alpha (TGFa) is a principal involved in normal and neoplastic development of the molecule in the normal and neoplastic development of the mammary gland is the EGFR and its extended family mammary gland. Binding of TGFc( to the epidermal of related receptors and peptide ligands (Table 1) . growth factor receptor (EGFR), activates the EGFRs' EGFR and the ligand TGFi, have expression levels endogenous tyrosine kinase activity and stimulates altered in the development of cancer in numerous growth of the epithelium in the virgin and pregnant issues. The related family of ligands that bind to mouse mammary gland. TGFa expression can be these receptors; EGF, heregulin, amphiregulin, and detected in breast cancer cells in vivo and in vitro and cripto also display alterations in their expression and overexpression can elicit partial transformation or activity within the pre-neoplastic and transformed cell immortalized human and rodent mammary epithelial (for a review see (Dickson and Lippman, 1995; cells. Despite evidence implicating TGF7 in the develop- Gullick et al., 1999; Schroeder and Lee, 1997) ). ment of mammary neoplasia, the actual mechanism of Despite the well characterized role of the EGFR and TGFR-induced transformation is unclear. Transgenic TGFGx in normal mammary growth signaling, in mouse models targeting heterologus TGFc to the transformation of mammary epithelial cells in vitro mammary gland have established TGFo overexpression and in vivo and their elevated expression in some can induce hyperproliferation, hyperplasia and occasional breast cancers, the specific alterations of the EGFR carcinoma. These transgenic studies demonstrated a signaling mechanism that lead to TGFa-initiated facilitating, proliferative role for TGFa in the develop-neoplasia are poorly understood. In an attempt to ment of neoplasia and implicated several oncogenes that elucidate these alterations, several transgenic mouse can cooperate with TGF7 to transform the mammary models have been generated to explore the role of epithelium. From studies of EGFR signaling pathways, TGF7 and EGFR in mammary neoplasia. This inhibitory and modulating agents such as anti-EGFR review will focus on TGFa and its role in antibodies and specific kinases inhibitors have been used transformation of the mammary gland. In addition, to block the action of this pathway and prevent the it will examine those studies that have attempted to development of TGFi-induced neoplasia and tumor identify the mechanisms of TGFo action in the formation. Studies in Stat5a knockout mice have mammary gland and those molecules that are established that the JAK2/Stat5a pathway can facilitate capable of cooperatively interacting with TGFot to the survival of the mammary epithelium and can impact promote tumorigenesis. the progression of TGFR-mandated mammary tumorigenesis. Together these experiments indicate that TGFal and the EGFR signaling pathway are potentially proliferation in vivo amenable to therapies for treatment of human breast disease. Oncogene (2000) 19, 1085-1091.
TGFcý is structurally and functionally similar to EGF; the peptides share a 42% identity and can elicit the Keywords: TGF alpha; mammary gland; transformasame biological effects in cultured mammary epithelial tion; cancer; mouse models; transgenic cells and explants (Daniel and Silberstein, 1985; Salomon et al., 1987; Vonderhaar, 1987) . TGFc• is often co-expressed with the EGFR and binding to the receptor activates the EGFRs' endogenous tyrosine Introduction kinase activity. Mammary epithelial cell lines can be stimulated to proliferate by TGFo6 (Smith et al., 1989; Development and progression of breast cancer, like Zajchowski and Sager, 1991) and it can act as an many other types of human cancer, is dependent on autocrine growth factor in normal and immortalized the progressive corruption and alteration of normal human mammary epithelial cells. TGFa autocrine and signaling pathways. Signaling mechanisms that proliferative activity can be blocked in these cells by an transmit growth signals are a predominant target anti-EGFR antibody (Bates et al., 1990; for carcinogenic and oncogenic alterations as they 1993). often confer a growth advantage to the pre-neoplastic
In normal mammary gland development, TGFc• and cell. One of the primary growth factor receptors EGF transcripts can be detected in the ductal and lobuloalveolar stages. The virgin mouse mammary gland expresses TGFcx in the proliferative cap cells and the stromal fibroblasts around the neck of the (Robertson et al., 1996) .
EGF EGFR
Only a small proportion of breast cancers has elevated TGFa EGFR levels of EGFR (Slamon et al., 1987) , or amplification Amphiregulin EGFR of EGFR (Peters and Wolff, 1983 breast.
Glial growth factor ?
TGFco can modulate cellular transformation in breast cancer cell lines. In the immortalized human Cripto-l ? unique receptor and erbB4 breast cancer cell line, MCF-7, TGFoi transfected cells that expressed EGFR were stimulated to grow in a colony forming assay (Ciardiello et al., 1990) . In a parallel study with fully transformed MCF-7 cells that lacked EGFR, TGF•o transfection did not effect a positive growth advantage (Clarke et al., 1989) . to the luminal ductal epithelium (Snedeker et al., 1991) .
Overexpression of TGFa in the immortalized mouse In the absence of ovarian steroids, exogenous TGFoc mammary cell line, NOG-8, generated anchorage and EGF can stimulate ductal growth of the mouse independent growth but colonies failed to form mammary epithelium suggesting that they can act tumors in nude mice (Shankar et al., 1989) . Thereindependently of secondary signals (Snedeker et al., fore, expression of TGFit is associated with the ability 1991). EGF and TGFit mRNA is present in pregnant to stimulate growth, while overexpression is allied with and lactating rat and human mammary glands and partial transformation in vitro and correlated with increases 2-3-fold over virgin levels at pregnancy appearance of carcinomas in vivo. (Liscia et al., 1990) . The EGFR is required for ductal development (Wiesen et al., 1999) and can be detected in both the stromal and epithelial components of the virgin mammary gland (Coleman et al., 1988) . In the Mouse models have been developed to study the role pregnant gland, a rapid increase is observed during of TGFct in the transformation and development of the midpregnancy precisely at the time of extensive cellular mammary gland. Several promoters have been utilized proliferation (Edery et al., 1985) . After pregnancy, the to target TGFoc both non-specifically and specifically to levels of EGFR decrease significantly. The coincident the mammary gland. These mouse models have expression of TGFc7 and its receptor with the established the importance of TGFoc in the early proliferative phases of mammary epithelial growth stages of neoplastic development of the mammary and TGFcts' direct mitogenic effect on epithelium in gland. vitro and in vivo confirms the functional role for this Initial studies demonstrating the neoplasia-promotsignaling dyad in the development and proliferation of ing activity of TGFoc were described in mice expressing the mammary epithelium.
human TGFct under the control of the zinc-inducible metallothionein (MT) promoter (Jhappan et al., 1990) .
TGFcC expression is associated with human breast cancer
Despite the fact that expression of the transgene was low in the mammary gland and was generally not TGFct is expressed and mitotically active in numerous inducible, these mice displayed increased cellular breast cancer cell lines and has been directly proliferation and delayed epithelial penetration of the implicated as a modulator of transformation in vivo stromal fatpad during ductal development. In a second (Borellini and Oka, 1989; Daniel and Silberstein, 1985;  parallel study, using the MT promoter directing the de Jong et al., 1998a; Salomon et al., 1984;  Valverius expression of rat TGFoc, Sandgren and colleagues et al., 1989) . In fact, the discovery of TGFit was based noticed that mice that had passed through multiple on its ability to transform retrovirally-infected pregnancies developed hyperplastic nodules and cultured fibroblasts (Todaro et al., 1980; dysplasia of the mammary epithelium (Sandgren et and Todaro, 1978) . Expression of TGFtx has been al., 1990). Only one mouse developed a secretory identified in pleural effusions from normal mammary adenocarcinoma. These studies demonstrated that there gland (Arteaga et al., 1988) , in invasive ductal was an association between the in vivo expression of carcinoma (Pilichowska et al., 1997) and correlates TGFcx and the development of mammary hyperplasia. with increased neo-angiogensis (de Jong et al., 1998b) A study directing TGFit expression specifically to in breast tumors. Carcinomas of the breast that have the mammary gland with the mouse mammary tumor higher level expression of TGFa also express high virus (MMTV) promoter demonstrated unequivocally levels of EGFR, implicating a functional role for the the growth and neoplasia promoting activity of TGFct TGFoc/EGFR autocrine loop in tumors (Umekita et (Matsui et al., 1990) . Precocious alveolar development, al., 1992) . The correlation between levels of EGFR hyperproliferation and hyperplasias were apparent in expression and neoplastic transformation in vivo is the mature virgin mouse. The alveolar hyperplasia was controversial (Gullick and Srinivasan, 1998) . Robert-present in glands from mature virgin mice, but not in immature virgin mice, suggesting a requirement for and decreased latency of tumors. In addition, the secondary inputs from systemic hormones for any process of involution, in which the gland absorbs and TGFc-dependent hyperplasia to occur. Hyperplastic reorganizes a significant portion of its epithelial alveolar nodules and cysts were prominent in the structure, was delayed in these mice as it was in the multiparous animal and increased in hyperplastic and original MT mice (Sandgren et al., 1990) . Latency of dysplastic character with the number of pregnancies.
tumor appearance was decreased in comparison to the One multiparous mouse developed adenocarcinomas MMTV-TGFoc model, but still required several rounds although none were metastatic. A second study was of pregnancy for initial tumor development. A majority performed with the MMTV-TGFot mice that studied in of the tumors were well-differentiated glandular greater detail the generation of hyperplasia and tumors adenomas or carcinomas (53%) and fibroadenomas (Halter et al., 1992) . At one year, 65% of multiparous (35%) and retained the glandular characteristics of late and 45% of virgin mice displayed hyperplasia. By 16 pregnant mammary epithelium. The appearance of months, 40% of the multiparous and 30% of the virgin multiple types of tumor and the retention of normal mice and mice had generated tumors. These studies glandular morphologies suggested that these different demonstrated that TGFY could stimulate the proliferatypes were stages of TGFc-dependent tumor progrestion of the mammary epithelium and generate sion. Interestingly, the levels of cyclinDl were elevated proliferative late pregnancy mammary gland pheno-in the WAP-TGFot transgenic glands. The targeted types in early pregnant animals. In addition, the overexpression of this cell cycle regulatory molecule is hyperplasia, dysplasia and frank carcinoma observed known to effect mammary transformation (Wang et al. , with this mouse model suggested that there was a 1994) and is in a chromosomal region frequently multistage nature to the progression of TGFc-initiated rearranged in human breast cancer (Dickson et al., transformation. 1995; Gillett et al., 1994 Gillett et al., , 1996 Gillett et al., , 1999 . This indicates A more dramatic mammary phenotype was achieved that cyclinDl may be a cooperative factor in the by targeting rat TGFo7 exclusively to the mammary development of TGFc induced mammary carcinogengland with the WAP-TGFo6 transgenic mouse (Sandg-esis. The delay in involution was suggested as a ren et al. , 1995) . This transgenic model achieved high mechanism for promoting transformation of the level TGFc* expression during pregnancy and lactation mammary gland as it provided an expanded populaand displayed similar proliferative mammary gland tion of proliferative epithelial cells that could be phenotypes as described in the MT and MMTV predisposed to transformation. This seminal paper transgenic models but with an increased incidence demonstrated TGFca could transform the mammary
Involution is enhanced in the absence of Stat5a. Hemotoxylin and eosin staining of inguinal mammary glands from Stat5a null non-transgenic (NTGKO), wildtype (WT), Stat5a null TGFi transgenic (KOTG) and TGFa. transgenic (TG) mice at 18 days of pregnancy (plS/a -d), days I (il/e -h), 3 (i3/i-1) and 7 (i7/m-p) of involution. Samples were collected from mice in or immediately after their first pregnancy. Compare epithelial condensation at day 3 and 7 of involution in the wildtype (l-j) versus the KOTG (I-k) and TG (1-1). Magnification is defined by the bar in a =200 pm. Reproduced with permission (Humphreys and Hennighausen, 1999) epithelium and suggested a possible mechanism for 1988) and in rodent mammary epithelial cell lines neoplastic development. The observation that TGFot transfected with myc, TGFcz could cooperate to could cause a delay in involution was supported by support a transformed phenotype (Telang et al. , results from a separate study with MT-TGFca mice 1990) . Mice that overexpressed both c-myc and TGFcx . An increase in DNA synthesis in in the mammary gland had an increased tumor lactation was accompanied by a significant decrease in incidence and decreased tumor latency when comapoptotic cells after 2 days of involution. Involution pared to c-myc transgenics (Amundadottir et al., was also affected in a mouse model utilizing WAP-1995) . A second paper utilizing the same bitransgenic TGFo and the Stat5a knockout mouse (Humphreys mice demonstrated that the synergism between these and Hennighausen, 1999). In the absence of Stat5a, two proteins was due to a cooperative growth apoptosis levels rose in the mammary gland during stimulus and inhibition of c-myc-induced apoptosis pregnancy and involution. This increase in apoptosis by TGFoc (Amundadottir et al., 1996) . Apoptotic enhanced involution of the WAP-TGFa gland ( Figure  tumors were present exclusively in mice that 1) and increased the latency of WAP-TGFcx-induced expressed only c-myc. In cell lines derived from these tumors. This result demonstrated the WAP-TGFc-tumors, exogenous TGFa could inhibit apoptosis. induced delay in involution and tumor formation, These data again implicated TGFax as a survival could be abrogated by a downstream signaling factor in the mammary epithelium. Interestingly, molecule that regulates cell death in the mammary tumor cells from the mammary glands of these epithelium.
bitransgenic mice could only become apoptotic when Subsequent studies examined the role that onco-exposed to a specific inhibitor of the EGFR kinase genes may play in acting cooperatively with TGFcx to pathway. This result suggested that an intact TGFc</ promote mammary transformation. The oncogene c-EGFR autocrine loop was required to mediate the myc is overexpressed in 25-30% of breast cancer survival effects of TGFo. (Bonilla et al., 1988; Callahan and Campbell, 1989;  Interaction between TGFot and the proto-oncogene Mariani-Costantini et al., 1988 , 1989 Morse et al., neu was examined in bitransgenic mice expressing both Figure 2 Model of the TGFo!/EGF signal transduction pathway and EGFR signaling inhibitors that affect EGFR-mediated transformation. EGF and TGFa! binding to the EGFR stimulate the activation of the endogenous receptor tyrosine kinase. The membrane-bound EGFR kinase activates one of several intracellular signal transduction pathways including the protein kinase A, Ras/Raf/MAPK, c-src and Jak/Stat pathways. Direct or indirect phosphorylation and activation of one or more of the Stat proteins, 1, 3, 5a, and 5b can be achieved through several of these mechanisms. The activating kinase, attributes of the targeted Stat and phosphorylated residue can elicit distinct functional consequences for the cell. Multiple intercellular pathways can lead to activation of the Stats and other nuclear factors like myc and cyclinD 1. Each of these pathways can be blocked by specific inhibitors (shown in red Italics). The proliferative stimulus provided by TGFa and EGF in cooperation with transforming oncogenes can lead to cellular transformation. Consequently, a clear understanding of the mechanisms involved and the use of multifocal inhibitors of signaling intermediaries is critical for effectual inhibition of EGFR signal transduction. Some alternative and intermediary intercellular signaling molecules have been omitted for clarity Oncogene TGF alpha and mouse models RC Humphreys and L Hennighausen 1089 genes under the control of the MMTV promoter tion from multipregnancy or after treatment with the . The neu proto-oncogene is a carcinogen DMBA supporting the theory that that member of the EGFR family and although it does not EGFR signaling is important in the initial stage of bind to TGFc7 or EGF, it can form heterodimers with neoplastic development. The EGFR can activate the the EGFR and it is often found overexpressed and intracellular tyrosine kinases Jaki and the transcripamplified in human breast cancers (Slamon et al., tion factors Statl, 3 and 5b in response to growth 1987). Tumor latency was decreased in the bitrans-signaling from EGF (Leonard and O'Shea, 1998) . genic mice, compared to the TGFci and neu, mono-Recent data has demonstrated that growth hormone transgenic lines. At 150 days 95% of the bitransgenic activated Ras/Raf/MAPK pathway can directly mice had mammary tumors vs 6% and 35% for the activate the normally cytokine-activated pathway of TGFca and neu mice, respectively. Bitransgenic tumors Stat5a (Pircher et al., 1999) and EGF can phosphorwere multifocal whereas mono-transgenic lines gener-ylate Stat5a through c-src (Olayioye et al., 1999) . ated focal tumors and contained activated neu. This Stat5a, a prolactin-activated transcription factor, has paper suggested a novel mechanism for TGFc7 an established role in the development and differcooperativity involving the transactivation of neu entiation of the lactation-competent mammary gland through the EGFR. Treatment of MMTV-TGFoý (Liu et al., 1987) but is also associated with signaling mice with the tumor promoter 7, 12 dimethyl in tumor cells (Hayakawa et al., 1998; Richer et al., benzanthracene demonstrated that TGFGi could 1998; Yu et al., 1997; Zhang et al., 1996) . Stat5a-null accelerate tumor formation and the authors suggested mice interbred with WAP-TGFc• transgenic mice that TGFc could act as a tumor promoter (Coffey et revealed inhibition of TGFo-dependent MAPK al., 1994) .
activation and TGFcz-dependent apoptosis inhibition These studies on the mechanism of TGFci-mediated after deletion of Stat5a. The increase in apoptosis tumorigenesis and cooperativity in the mammary permitted a more complete epithelial regression to gland demonstrate that the overexpression of TGFcg occur at involution (Figure 1) . A more complete gives the preneoplastic mammary epithelium a regression deleted a significant number of potentially proliferative advantage but in and of itself is not a neoplastic cells and this impacted WAP-TGFc driven transforming event. Secondary events, like the tumorigenesis. Stat5a null/WAP TGFc• transgenic activation of proto-oncogenes, can significantly mice had an increase in tumor latency when increase the efficiency with which TGFa can trans-compared to the WAP-TGFc* transgenic. These mice form the mammary epithelium. Importantly, these displayed an increase in apoptosis before and during studies support the theory that TGFc's influence on involution. These data suggested Stat5a was acting as the regulation of apoptosis in the mammary gland is a a survival factor for the mammary epithelium by possible mechanism of promoting survival of the blocking the onset of apoptosis. Theoretically, the neoplastic cell.
absence of Stat5a permitted apoptosis to occur and thereby diminished the pool of potential neoplastic cells that could become transformed (Humphreys and Disruption of TGFc• signaling and potential therapies for Hennighausen, 1999) . breast cancer A novel mechanism of inhibition of TGFca activity
The EGFR is required for mammary gland ductal was demonstrated recently in human mammary development (Wiesen et al., 1999; Xie et al., 1997) epithelial cells with an anti-metalloproteinase. Metaland, as described previously, is aberrantly expressed in loproteinases are extracellular enzymes that cleave 40% of human breast cancers and occasionally components of the extracellular matrix including the overexpressed in those tumors with poor prognosis. EGFR ligands; TGFoý and EGF. This cleavage event This receptor can interact with several distinct ligands releases them from the cell surface rendering the (Table 1 ) and activates different intracellular and growth factor into an active form. These metallopronuclear signaling pathways (Figure 2 ). Substrates for teinase inhibitors prevented TGFa release from the this type 1 receptor tyrosine kinase are numerous and cell surface, blocked cell migration and decreased demonstrate the influence of EGFR on the regulation proliferation. Additionally, the metalloproteinase of cellular growth. Importantly, it is clear that this inhibitors reduced the growth of EGF-dependent receptor plays a central role in the development and tumor cell lines and could synergize with anti-EGFR progression of human breast cancer. Therefore, insight antibodies (Dong et al., 1999) . into EGFR signal transduction and the mechanism of Therapies for inhibiting the action of EGFR and substrate selection and activation are critical to indirectly the action of TGFc*, to block tumorigenesis understanding the development of breast cancer. The are being explored. Current research into the action of EGFR and its interaction with TGFa has been and molecules that may have a role in regulating the continues to be a target for potential anti-cancer TGFcx signaling pathway like EGFR-specific monotherapies that aim to regulate its activity and signaling clonal antibodies (Ciardiello et al., 1999) , protein mechanisms.
kinase A inhibitors, a combination of antibodies and A recent study demonstrated that inhibition of the chemotheraputic agents (Bianco et al., 1997 ; Ciardiello signal from EGFR to its intracellular signaling et al., 1996; Ciardiello and Tortora, 1998) , antimolecules is critical in blocking tumor progression. estrogens like taxol, raloxifen, alone or in combina-Treatment of MMTV-TGFcx transgenic mice with a tion with antibodies like the humanized monoclonal farnesyl transferase inhibitor, which blocks Ras antibody to neu; Herceptin (Brenner and Adams, function, demonstrated a significant regression of 1999; Hanna et al., 1999; Robertson, 1998 ; Ross and mammary tumors (Norgaard et al., 1999) . This Fletcher, 1998) , provide some promising results for inhibitory effect was ineffectual after tumor accelera-future treatment of breast cancer.
